Recent advances in oncolytic adenovirus therapies for cancer
Authors:
- 1 December 2016
- journal article
- review article
- Published by Elsevier in Current Opinion in Virology
- Vol. 21, 9-15
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R00HL098692, T32HL092332)
This publication has 44 references indexed in Scilit:
- Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in MicePLOS ONE, 2016
- Immunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesViruses, 2015
- Oncolytic viruses get a boost with first FDA-approval recommendationNature Reviews Drug Discovery, 2015
- Immunological Effects of a Tumor Necrosis Factor Alpha–Armed Oncolytic AdenovirusHuman Gene Therapy, 2015
- Going viral with cancer immunotherapyNature Reviews Cancer, 2014
- Therapeutic Effect of Oncolytic Adenovirus Expressing Relaxin in Radioresistant Oral Squamous Cell CarcinomaOncology Research, 2012
- Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradationGene Therapy, 2012
- Potent Antitumor Activity of Oncolytic Adenovirus Expressing mda-7/IL-24 for Colorectal CancerHuman Gene Therapy, 2005
- Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.2002
- The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissuesAPMIS, 1998